ORIC Pharmaceuticals picked a fighting-weight dose for its prostate cancer drug last week. The market did not like the company it chose to fight alongside.
The South San Francisco biotech announced March 31 it would advance rinzimetostat into a Phase 3 trial called Himalayas-1, pairing the PRC2 inhibitor with darolutamide, a less widely used androgen receptor inhibitor. The dose was sensible: 400 milligrams once daily, selected over a higher 600 mg option that showed comparable efficacy but statistically significant increases in toxicity and treatment modifications. The safety profile was clean — one Grade 3 treatment-related adverse event across 33 patients, no Grade 4 or 5 events. ORIC stock fell 27 percent on the news.
The drop was not about the dose. It was about the dance partner.
Rinzimetostat is a third-generation PRC2 inhibitor targeting the EED subunit of the polycomb repressive complex 2, an epigenetic silencing mechanism that prostate cancer cells co-opt to suppress tumor suppressor genes. ORIC positions it ahead of tazemetostat, Ipsen's now-withdrawn first-generation PRC2 inhibitor, and mevrometostat, Pfizer's second-generation EZH2 inhibitor that reached Phase 2 before development stalled. According to its press release, ORIC noted that PRC2 dysregulation is associated with poor outcomes in metastatic castration-resistant prostate cancer, making it a rational target in a disease that has largely exhausted conventional hormone pathways.
Darolutamide, sold as Nubeqa by Bayer, blocks testosterone from binding the androgen receptor, starving the tumor of androgen-driven growth signals. The combination is mechanistically plausible: rinzimetostat reverses epigenetic suppression of tumor suppressors while darolutamide cuts the androgen signal at the receptor.
The early clinical data looked respectable. In the dose-escalation cohort, 47 percent of patients achieved a PSA50 response — meaning their prostate-specific antigen levels fell by at least half — with 33 percent confirmed. Seventy-one percent of evaluable patients achieved greater than 50 percent reduction in circulating tumor DNA. The five-month radiographic progression-free survival landmark sat at 84 percent. These are not the numbers of a drug that is clearly broken.
The puzzle starts when you ask what Himalayas-1 is actually testing against. The trial will enroll approximately 600 patients at over 250 sites in more than 20 countries, randomized one-to-one against physician's choice of standard of care. That means enzalutamide, abiraterone, or other approved therapies — the drugs that most metastatic castration-resistant prostate cancer patients actually receive. ORIC estimates the U.S. addressable market at more than $3.5 billion, with a global market of $7 billion.
That market is dominated by enzalutamide and abiraterone. Darolutamide is approved in the indication but is not the leading drug in the class. So why pair rinzimetostat with a secondary androgen receptor inhibitor in a Phase 3 designed to demonstrate it can beat the standard of care? The answer, most likely, is the mevrometostat precedent.
Pfizer's mevrometostat is a second-generation PRC2 inhibitor targeting EZH2, a different subunit than rinzimetostat's EED, but the class similarity means its toxicity findings are relevant. When mevrometostat was combined with enzalutamide in earlier clinical work, the combination produced Grade 3 diarrhea in 78 percent of patients and Grade 3 fatigue in 43 percent — rates that made the regimen effectively untenable for chronic use in a palliative prostate cancer setting. According to data ORIC cited in its SEC filing, mevrometostat plus enzalutamide showed Grade 3 fatigue in 43 percent of patients and Grade 3 diarrhea in 78 percent. Rinzimetostat plus darolutamide showed Grade 1 or 2 diarrhea in 22 percent of patients and Grade 1 or 2 fatigue in 39 percent, with no Grade 3 or higher events attributed to either drug.
The cleaner toxicity profile with darolutamide may reflect a real pharmacologic interaction difference. Or it may reflect that darolutamide is simply a less potent androgen receptor inhibitor than enzalutamide, producing fewer overlapping side effects because it is doing less work.
If Himalayas-1 succeeds, ORIC will have data showing rinzimetostat plus darolutamide beat physician's choice. But physician's choice skews heavily toward enzalutamide and abiraterone. The trial will not directly demonstrate that rinzimetostat plus darolutamide is better than rinzimetostat plus enzalutamide, because that arm does not exist. A physician reading the Phase 3 results will have to decide whether a cleaner-looking combination using a secondary androgen receptor inhibitor is worth switching a patient away from the drug they were already on.
The market ORIC is chasing — metastatic castration-resistant prostate cancer patients previously treated with abiraterone — is real and substantial. Approximately 17,000 patients in the U.S. fall into this category annually. These are patients whose disease has progressed after front-line androgen receptor pathway inhibition — a genuinely hard-to-treat group with limited remaining options. A drug that works in this population has value regardless of which combination partner made it work.
But the commercial calculus is not purely clinical. Darolutamide is Bayer's drug. Enzalutamide is Astellas Pharma and Pfizer's. By building its registration pathway around darolutamide, ORIC has implicitly picked a commercial ally — or, more precisely, has avoided picking the dominant one.
PRC2 inhibitors have had a complicated journey. Ipsen voluntarily withdrew tazemetostat from all markets on March 9, 2026, after a safety signal in the SYMPHONY-1 trial related to secondary blood cancer risk. Whether rinzimetostat faces the same class-level risk is unknown. The EED subunit targeting is distinct enough from EZH2 targeting that the safety profile may diverge. But the PRC2 field has had enough surprises that investors are right to price in some uncertainty.
Himalayas-1 is sized to produce a registrational readout — 600 patients, randomized, with radiographic progression-free survival as the primary endpoint. If the combination shows a meaningful benefit over standard of care, ORIC will have a path to accelerated approval in a niche but valuable population. If it does not, or if the toxicity profile shifts at larger patient numbers, the 27 percent stock decline will look modest by comparison.
The dose choice was not the hard part. The hard part was deciding which fight to pick.
